Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis.

The Journal of infectious diseases·2025
Same author

Standards for clinical trials for treating TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2023
Same author

Male reproductive hormones in patients treated with pretomanid.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2022
Same author

Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2021
Same author

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2021
Same author

Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study.

BMC medicine·2018

Related Experiment Video

Updated: Jul 10, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Challenges associated with current and future TB treatment.

M Laurenzi1, A Ginsberg, M Spigelman

  • 1The Global Alliance for TB Drug Development, 80 Broad Street, 31st Floor, New York, NY 10004, USA. martino.laurenzi@tballiance.org

Infectious Disorders Drug Targets
|November 1, 2007
PubMed
Summary

Current tuberculosis (TB) treatment faces challenges due to drug resistance and complex protocols. This review discusses hurdles in optimizing existing drugs and developing new therapies for Mycobacterium tuberculosis (M. tb).

Related Experiment Videos

Last Updated: Jul 10, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Medicine

Background:

  • Current tuberculosis (TB) treatments rely on older drug regimens with high cure rates for drug-susceptible Mycobacterium tuberculosis (M. tb) if protocols are followed.
  • Challenges include complex treatment adherence, rising drug-resistant M. tb strains, and drug-drug interactions in HIV-TB coinfected patients, necessitating improved TB therapies.

Purpose of the Study:

  • To review the challenges and hurdles in optimizing current tuberculosis drug treatments.
  • To discuss the difficulties in developing novel and improved tuberculosis therapies.
  • To propose efficient processes for future TB drug development.

Main Methods:

  • Literature review and analysis of current challenges in tuberculosis drug development.
  • Focus on clinical development aspects of TB drugs.
  • Discussion of existing drug optimization and novel product development.

Main Results:

  • Identified significant hurdles in the optimized use of existing TB drugs.
  • Highlighted challenges inherent in the clinical development of new TB therapeutic products.
  • Recognized the urgent need for improved TB drugs and treatment protocols due to resistance and adherence issues.

Conclusions:

  • Optimizing current TB drugs and developing new ones face considerable challenges.
  • Efficient clinical development processes are crucial for advancing TB therapy.
  • Addressing drug resistance and treatment complexity is paramount for global TB control.